Form D · Pharmaceuticals
Savara Inc.
Austin, TX · CIK 0001461492
Offering snapshot reported Jul 18, 2016 · SEC filing
- Reported sold
- Yet to sell Offering amount: $5M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 18, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 2, 2016 | Amendment | $20,671,246 | $2,126,772vs Dec 17, 2015 | 206 | SEC filing |
| Dec 17, 2015 | Initial | $18,544,474 | No comparison | 125 | SEC filing |
| Oct 16, 2014 | Amendment | $10,000,000 | $0vs Oct 10, 2014 | 139 | SEC filing |
| Oct 10, 2014 | Initial | $10,000,000 | No comparison | 139 | SEC filing |
| Jun 26, 2014 | Amendment | $4,493,581 | $0vs Jun 10, 2014 | 56 | SEC filing |
| Jun 10, 2014 | Initial | $4,493,581 | No comparison | 56 | SEC filing |
| Jun 26, 2013 | Amendment | $14,398,895 | $7,500,389vs Jun 12, 2012 | 239 | SEC filing |
| Jun 12, 2012 | Initial | $6,898,506 | No comparison | 117 | SEC filing |
| Sep 21, 2010 | Amendment | $1,420,929 | $700,000vs Mar 11, 2010 | 23 | SEC filing |
| Mar 11, 2010 | Amendment | $720,929 | $75,929vs Dec 15, 2009 | 14 | SEC filing |
| Dec 15, 2009 | Initial | $656,157 | No comparison | 13 | SEC filing |
| Dec 15, 2009 | Amendment | $645,000 | -$11,157vs Dec 15, 2009 | 13 | SEC filing |
| Jun 8, 2009 | Initial | $833,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-267223
Subordinated Convertible Promissory Notes and Series C Preferred Stock Purchase Warrants
Source: Form D, filed Jul 18, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Benkendorf | Director |
| Cory Berkland | Executive |
| Curt Bilby | Director |
| Mike Ciesla | Executive |
| Matthew Dennis | Director |
| Nevan Elam | Director |
| Shirley Gee | Director |
| Rick Hawkins | Director |
| Richard Hawkins | Director |
| Taneli Jouhikainen | Executive |
| George Laurence | Director, Executive |
| John Lord | Executive |
| Chris Marich | Executive |
| Joseph S. Mc Cracken | Director |
| Joe Mc Cracken | Director |
| Robert Neville | Director, Executive |
| Yuri Pikover | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
900 S. Capital Of Texas Highway Suite 150
Austin, TX, 78746
Austin, TX, 78746